abstract |
The present disclosure relates to a pharmaceutical composition comprising esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained.The pharmaceutical composition comprising esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough. |